Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Follow-Up Questions
Prostatype Genomics AB のCEOは誰ですか？
Fredrik Persson は Prostatype Genomics AB の Chief Executive Officer で、2017 から在籍しています。
PGABF の株価パフォーマンスは？
PGABF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Prostatype Genomics AB の主な事業テーマや業界は？
Prostatype Genomics AB は Biotechnology 業界、セクターは Health Care に属しています。
